Skip to main content
Year archive

Marinomed Biotech AG — 2023 filings

All 41 regulatory filings released by Marinomed Biotech AG (MARI) in 2023, sourced directly from the official regulator.

41 Filings
2023 Period
2023 filings (41)
Filing Released Lang
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
Regulatory Filings
2023-12-18 English
M&A Activity 2023
M&A Activity
2023-12-18 English
Regulatory Filings 2023
Regulatory Filings
2023-12-18 German
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
M&A Activity
2023-12-18 English
Marinomed Biotech AG with new Carragelose distribution and manufacturing partners and EU patent
Environmental & Social Information
2023-12-14 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-11-30 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-11-30 German
Marinomed Biotech AG: Stable revenues in the first three quarters of 2023 and further progress in business development
Earnings Release 9M 2023
2023-11-21 English
Marinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume
Capital/Financing Update
2023-10-17 English
Interim / Quarterly Report 2023
Interim / Quarterly Report H1 2023
2023-08-17 English
Interim / Quarterly Report 2023
Interim / Quarterly Report H1 2023
2023-08-17 German
Marinomed Biotech AG reports record revenues in the first half of the year and pushes business development activities
Earnings Release H1 2023
2023-08-17 English
Marinomed enters first long-term Solv4U partnership with Shanghaibased SPH Sine Pharmaceutical Laboratories Co. Ltd.
M&A Activity
2023-08-09 English
Marinomed Biotech AG: M8 Pharmaceuticals obtains market authorization for Carragelose nasal spray in Mexico
Regulatory Filings
2023-07-27 English
Peer-reviewed publication by Marinomed Biotech AG and Friedrich-Alexander-University Erlangen-Nurnberg reconfirms broad virus-blocking effectiveness of iota-carrageenan
Regulatory Filings
2023-07-13 English
Marinomed Biotech AG: Annual General Meeting elects Dr. Eva Hofstadter-Thalmann as a new member of the Supervisory Board
AGM Information
2023-06-21 English
Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024
Environmental & Social Information
2023-06-15 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-06-01 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-06-01 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-06-01 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-06-01 German
Major Shareholding Notification 2023
Major Shareholding Notification
2023-06-01 German
Major Shareholding Notification 2023
Major Shareholding Notification
2023-06-01 German
AGM Information 2023
AGM Information
2023-05-23 English
AGM Information 2023
AGM Information
2023-05-23 German
Marinomed Biotech AG reports best first quarter in company history
Earnings Release Q1 2023
2023-05-23 English
Director's Dealing 2023
Director's Dealing
2023-04-21 English
Director's Dealing 2023
Director's Dealing
2023-04-21 German
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-04-19 German
Annual Report 2022
Annual Report FY 2022
2023-04-19 German
Annual Report 2022
Annual Report FY 2022
2023-04-19 German
Marinomed Biotech AG with Carragelose record sales in 2022 and positive outlook for 2023
Earnings Release FY 2022
2023-04-19 English
Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever
Legal Proceedings Report
2023-04-12 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-03-31 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-03-31 German
Marinomed Biotech AG reports positive clinical data for the Carragelose decongestant nasal spray
Regulatory Filings
2023-03-14 English
Marinomed Biotech AG announces preliminary revenue for 2022 with double-digit growth for Carragelose
Earnings Release FY 2022
2023-02-16 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-14 English
Director's Dealing 2023
Director's Dealing
2023-02-14 German
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-01-31 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-01-31 German